Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 22Glioblastoma 15Gliosarcoma 13Prostatic Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Breast Neoplasms 11Head and Neck Neoplasms 10Pancreatic Neoplasms 9Lung Neoplasms 9Brain Neoplasms 7Adenocarcinoma of Lung 6Salivary Gland Neoplasms 5Astrocytoma 5Rectal Neoplasms 4Neoplasm Metastasis 4Glioma 4Central Nervous System Neoplasms 4Carcinoma, Intraductal, Noninfiltrating 4Adenocarcinoma, Bronchiolo-Alveolar 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Stomach Neoplasms 3Sarcoma 3Ovarian Neoplasms 3Oligodendroglioma 3Liver Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Carcinoma, Ductal, Breast 3Wilms Tumor 2

Interventions

Cytarabine 6Vincristine 4Methotrexate 4Mercaptopurine 4pegaspargase 3merphos 3dexamethasone acetate 3dexamethasone 21-phosphate 3azathiopurine 3auricularum 3Thioguanine 3Dexamethasone 3Daunorubicin 3Cyclophosphamide 3Calcium Dobesilate 3Asparaginase 3prednylidene 2blinatumomab 2asparaginase erwinia chrysanthemi recombinant 2Prednisolone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Leucovorin 2Hydrocortisone 2Etoposide 2Doxorubicin 2hydrocortisone hemisuccinate 1deltacortene 1calaspargase pegol 1Spinal Puncture 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Down Syndrome × Radiotherapy, Conformal × Clear all
NCT04546399 2025-09-10

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
461 enrolled
Lymphoid

Burkitt Lymphoma, Down Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡